会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • ANTIBODIES TO SARS CORONAVIRUS
    • 抗SARS抗原
    • WO2008060331A2
    • 2008-05-22
    • PCT/US2007012136
    • 2007-05-21
    • AMGEN INCBABCOOK JOHN SPRABHAKAR BELLUR SCOUGHLIN MELISSA
    • BABCOOK JOHN SPRABHAKAR BELLUR SCOUGHLIN MELISSA
    • C07K16/00
    • C07K16/10A61K48/00C07K14/005C07K2317/21C07K2317/56C07K2317/565C07K2317/76C12N2770/20022
    • The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti- SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    • 本发明涉及特异性结合人SARS-CoV S蛋白的人抗体及其抗原结合部分的抗体,其功能是中和SARS-CoV。 本发明还涉及双特异性,衍生化的单链抗体或融合蛋白部分的抗体。 本发明还涉及衍生自人类抗SARS-CoV S蛋白抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗SARS-CoV S蛋白抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。
    • 3. 发明申请
    • ANTIBODIES TO SARS CORONAVIRUS
    • 抗SARS冠状病毒的抗体
    • WO2008060331A9
    • 2008-11-20
    • PCT/US2007012136
    • 2007-05-21
    • AMGEN INCBABCOOK JOHN SPRABHAKAR BELLUR SCOUGHLIN MELISSA
    • BABCOOK JOHN SPRABHAKAR BELLUR SCOUGHLIN MELISSA
    • C07K16/10
    • C07K16/10A61K48/00C07K14/005C07K2317/21C07K2317/56C07K2317/565C07K2317/76C12N2770/20022
    • The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human severe acute respiratory syndrome coronavirus (SARS-CoV S) protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and 'light chain immunoglobulins derived from human anti- SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also, provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of. the present invention.
    • 本发明涉及抗体,其包括与人严重急性呼吸综合征冠状病毒(SARS-CoV S)蛋白特异性结合的人抗体及其抗原结合部分,并且具有中和SARS-CoV的功能。 本发明还涉及双特异性,衍生化的单链抗体或融合蛋白部分的抗体。 本发明还涉及源自人抗SARS-CoV S蛋白抗体和编码这种免疫球蛋白的核酸分子的分离的重链和“轻链免疫球蛋白”。 本发明还涉及使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供了使用编码包含人抗SARS-CoV S蛋白抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含核酸分子的转基因动物或植物。 本发明。